keyword
MENU ▼
Read by QxMD icon Read
search

metabolism and heart failure

keyword
https://www.readbyqxmd.com/read/28915840/evolution-and-bad-prognostic-value-of-advanced-glycation-end-products-after-acute-heart-failure-relation-with-body-composition
#1
Beatriz Paradela-Dobarro, Ángel Fernández-Trasancos, Diana Bou-Teen, Sonia Eiras, Rocío González-Ferreiro, Rosa M Agra, Alfonso Varela-Román, Ana I Castro-Pais, Marcos C Carreira, Felipe F Casanueva, Ezequiel Álvarez, José R González-Juanatey
AIM: The role of advanced glycation end products (AGEs) and their soluble receptor (sRAGE) on the progression and prognosis of acute heart failure (HF) was analysed in relation with metabolic parameters as body composition and nutritional status. METHODS: A hundred and fifty consecutive patients were included in a prospective clinical study during hospitalization by acute HF. Detailed medical history, physical examination, electrocardiogram, echocardiogram and vein peripheral blood were taken for all patients...
September 15, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28915531/subclinical-hyperthyroidism-and-the-cardiovascular-disease
#2
Alessandro P Delitala
Thyroid hormone excess has complex metabolic effects, particularly on the cardiovascular system. Treatment of these conditions is universally suggested by international guidelines. Subclinical hyperthyroidism, defined by reduced or suppressed TSH levels in the presence of normal free thyroxine and free triiodothyronine values, is common in the general population and progressively increases with aging, being as high as 15.4% in subjects more than 75 years old and more frequent in subjects with nodular goiter...
September 15, 2017: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/28915332/obesity-and-cardiometabolic-defects-in-heart-failure-pathology
#3
Ganesh V Halade, Vasundhara Kain
Obesity is a major global epidemic that sets the stage for diverse multiple pathologies, including cardiovascular disease. The obesity-related low-grade chronic inflamed milieu is more pronounced in aging and responsive to cardiac dysfunction in heart failure pathology. Metabolic dysregulation of obesity integrates with immune reservoir in spleen and kidney network. Therefore, an integrative systems biology approach is necessary to delay progressive cardiac alternations. The purpose of this comprehensive review is to largely discuss the impact of obesity on the cardiovascular pathobiology in the context of problems and challenges, with major emphasis on the diversified models, and to study cardiac remodeling in obesity...
September 12, 2017: Comprehensive Physiology
https://www.readbyqxmd.com/read/28912917/the-low-dose-7-5-mg-day-pioglitazone-therapy
#4
REVIEW
Hidekatsu Yanai, Hiroki Adachi
Pioglitazone is one of thiazolidinedione derivatives, which stimulates nuclear peroxisome proliferator-activated receptor gamma and improves glucose and lipid metabolism and insulin sensitivity. A recent systematic review and meta-analysis showed that pioglitazone therapy was associated with a lower risk of major adverse cardiovascular events in patients with pre-diabetes and diabetes. Further, in a cohort study of patients with type 2 diabetes, pioglitazone therapy was associated with a statistically significant decrease in the risk of all-cause mortality...
October 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28911506/metabolically-healthy-obese-and-incident-cardiovascular-disease-events-among-3-5%C3%A2-million-men-and-women
#5
Rishi Caleyachetty, G Neil Thomas, Konstantinos A Toulis, Nuredin Mohammed, Krishna M Gokhale, Kumarendran Balachandran, Krishnarajah Nirantharakumar
BACKGROUND: Previous studies have been unclear about the cardiovascular risks for metabolically healthy obese individuals. OBJECTIVES: This study examined the associations among metabolically healthy obese individuals and 4 different presentations of incident cardiovascular disease in a contemporary population. METHODS: We used linked electronic health records (1995 to 2015) in The Health Improvement Network (THIN) to assemble a cohort of 3...
September 19, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28902230/chronic-kidney-disease-and-metabolic-syndrome-as-risk-factors-for-cardiovascular-disease-in-a-primary-care-program
#6
Suzana Greffin, Mauro Barros André, Jorge Paulo Strogoff de Matos, Hye Chung Kang, Antonio José Lagoeiro Jorge, Maria Luiza Garcia Rosa, Jocemir Ronaldo Lugon
Introduction: Cardiovascular disease (CVD) is especially prevalent in patients with chronic kidney disease (CKD). Objective: To evaluate the role of CKD and metabolic syndrome (MS), which is a cluster of risk factors for CVD, as predictors of CVD. Methods: Observational, cross-sectional study with a random sample aged 45 or more years extracted from the population assisted by the primary care program in Niterói city in the state of Rio de Janeiro, Brazil...
August 28, 2017: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/28894049/the-pathophysiological-basis-of-the-protective-effects-of-metformin-in-heart-failure
#7
Aleksandra Dziubak, Grażyna Wójcicka
Metformin, currently recommended as the drug of first choice in type 2 diabetes mellitus (T2DM), is one of the few antihiperglycemic drugs to reduce cardiovascular risk. Nonetheless, due to the risk of lactic acidosis during metformin therapy, its usage in patients with diabetes and heart failure (HF) is still a matter of debate. The aim of this review is to present data supporting the possibility of using metformin in the treatment of diabetic patients with concomitant heart failure. In the failing heart, metformin through the mechanism related to AMP-activated protein kinase (AMPK) activity, improves free fatty acids (FFA) and glucose metabolism, mitochondrial biogenesis, as well as nitric oxide (NO)-NO synthase pathway...
August 24, 2017: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/28893184/the-canadian-hiv-and-aging-cohort-study-determinants-of-increased-risk-of-cardio-vascular-diseases-in-hiv-infected-individuals-rationale-and-study-protocol
#8
Madeleine Durand, Carl Chartrand-Lefebvre, Jean-Guy Baril, Sylvie Trottier, Benoit Trottier, Marianne Harris, Sharon Walmsley, Brian Conway, Alexander Wong, Jean-Pierre Routy, Colin Kovacs, Paul A MacPherson, Kenneth Marc Monteith, Samer Mansour, George Thanassoulis, Michal Abrahamowicz, Zhitong Zhu, Christos Tsoukas, Petronela Ancuta, Nicole Bernard, Cécile L Tremblay
BACKGROUND: With potent antiretroviral drugs, HIV infection is becoming a chronic disease. Emergence of comorbidities, particularly cardiovascular disease (CVD) has become a leading concern for patients living with the infection. We hypothesized that the chronic and persistent inflammation and immune activation associated with HIV disease leads to accelerated aging, characterized by CVD. This will translate into higher incidence rates of CVD in HIV infected participants, when compared to HIV negative participants, after adjustment for traditional CVD risk factors...
September 11, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28890470/circulating-angptl2-levels-increase-in-humans-and-mice-exhibiting-cardiac-dysfunction
#9
Zhe Tian, Keishi Miyata, Jun Morinaga, Haruki Horiguchi, Tsuyoshi Kadomatsu, Motoyoshi Endo, Jiabin Zhao, Shunshun Zhu, Taichi Sugizaki, Michio Sato, Kazutoyo Terada, Takahiro Okumura, Toyoaki Murohara, Yuichi Oike
BACKGROUND: Recently, it was reported that angiopoietin-like protein 2 (ANGPTL2) secreted from a pathologically stressed heart accelerates cardiac dysfunction in an autocrine/paracrine manner, and that suppression of ANGPTL2 production in the heart restored cardiac function and myocardial energy metabolism, thereby blocking heart failure (HF) development. Interestingly, circulating ANGPTL2 concentrations reportedly increase in HF patients, suggesting a possible endocrine effect on cardiac dysfunction...
September 8, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28888034/blunting-of-estrogen-modulation-of-cardiac-cellular-chymase-ras-activity-and-function-in-shr
#10
Sarfaraz Ahmad, Xuming Sun, Marina Lin, Jasmina Varagic, Gisele Zapata-Sudo, Carlos M Ferrario, Leanne Groban, Hao Wang
The relatively low efficacy of ACE-inhibitors in the treatment of heart failure in women after estrogen loss may be due to their inability to reach the intracellular sites at which angiotensin (Ang) II is generated and/or the existence of cell-specific mechanisms in which ACE is not the essential processing pathway for Ang II formation. We compared the metabolic pathway for Ang II formation in freshly isolated myocytes (CMs) and non-myocytes (NCMs) in cardiac membranes extracted from hearts of gonadal-intact and ovariectomized (OVX) adult WKY and SHR rats...
September 9, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/28886529/peroxisome-proliferator-activated-receptors-as-therapeutic-targets-for-heart-failure
#11
REVIEW
Abdelrahman Ibrahim Abushouk, Mostafa Wanees Ahmed El-Husseny, Eshak I Bahbah, Ahmed Elmaraezy, Aya Ashraf Ali, Asmaa Ashraf, Mohamed M Abdel-Daim
Heart failure (HF) is a common clinical syndrome that affects more than 23 million individuals worldwide. Despite the marked advances in its management, the mortality rates in HF patients have remained unacceptably high. Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription regulators, involved in the regulation of fatty acid and glucose metabolism. PPAR agonists are currently used for the treatment of type II diabetes mellitus and hyperlipidemia; however, their role as therapeutic agents for HF remains under investigation...
September 5, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28883044/beneficial-effects-of-exercise-training-in-heart-failure-are-lost-in-male-diabetic-rats
#12
Dalila Boudia, Valérie Domergue, Phlippe Mateo, Loubina Fazal, Mathilde Prud'homme, Heloise Prigent, Claude Delcayre, Alain Cohen-Solal, Anne Garnier, Renee Ventura-Clapier, Jane-Lise Samuel
Exercise training has been demonstrated to have beneficial effects in patients with heart failure (HF) or diabetes. However, it is unknown whether diabetic patients with HF will benefit from exercise training. Male Wistar rats were fed either a standard (Sham, n= 53) or high-fat, high-sucrose (HFHS) diet (D, n=66) for 6 months. After 2 months of diet, the rats were already diabetic. Rats were then randomly subjected to either myocardial infarction by coronary artery ligation (MI) or sham operation (Sham). Two months later, heart failure was documented by echocardiography and animals were randomly subjected to exercise training with treadmill for eight additional weeks or remained sedentary...
September 7, 2017: Journal of Applied Physiology
https://www.readbyqxmd.com/read/28878952/pathophysiology-of-exercise-intolerance-in-chronic-diseases-the-role-of-diminished-cardiac-performance-in-mitochondrial-and-heart-failure-patients
#13
Jodi McCoy, Matthew Bates, Christopher Eggett, Mario Siervo, Sophie Cassidy, Jane Newman, Sarah A Moore, Grainne Gorman, Michael I Trenell, Lazar Velicki, Petar M Seferovic, John G F Cleland, Guy A MacGowan, Doug M Turnbull, Djordje G Jakovljevic
OBJECTIVE: Exercise intolerance is a clinical hallmark of chronic conditions. The present study determined pathophysiological mechanisms of exercise intolerance in cardiovascular, neuromuscular, and metabolic disorders. METHODS: In a prospective cross-sectional observational study 152 patients (heart failure reduced ejection fraction, n=32; stroke, n=34; mitochondrial disease, n=28; type two diabetes, n=28; and healthy controls, n=30) performed cardiopulmonary exercise testing with metabolic and haemodynamic measurements...
2017: Open Heart
https://www.readbyqxmd.com/read/28868039/relaxin-2-in-cardiometabolic-diseases-mechanisms-of-action-and-future-perspectives
#14
REVIEW
Sandra Feijóo-Bandín, Alana Aragón-Herrera, Diego Rodríguez-Penas, Manuel Portolés, Esther Roselló-Lletí, Miguel Rivera, José R González-Juanatey, Francisca Lago
Despite the great effort of the medical community during the last decades, cardiovascular diseases remain the leading cause of death worldwide, increasing their prevalence every year mainly due to our new way of life. In the last years, the study of new hormones implicated in the regulation of energy metabolism and inflammation has raised a great interest among the scientific community regarding their implications in the development of cardiometabolic diseases. In this review, we will summarize the main actions of relaxin, a pleiotropic hormone that was previously suggested to improve acute heart failure and that participates in both metabolism and inflammation regulation at cardiovascular level, and will discuss its potential as future therapeutic target to prevent/reduce cardiovascular diseases...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28867689/angptl2%C3%A3-a-new-causal-player-in-accelerating-heart-disease-development-in-the-aging
#15
Yuichi Oike, Zhe Tian, Keishi Miyata, Jun Morinaga, Motoyoshi Endo, Tsuyoshi Kadomatsu
In parallel with the increase in the number of elderly people worldwide, the number of patients with heart disease is also rapidly increasing. Of the heart diseases, cardiovascular disease (CVD) and heart failure (HF) are strongly associated with adverse health outcomes that decrease productivity in later years. Recently, ANGPTL2, a secreted glycoprotein and member of the angiopoietin-like protein family, has received attention as a causal player in the development of CVD and HF. Prolonged ANGPTL2 autocrine/paracrine signaling in vascular tissue leads to chronic inflammation and pathologic tissue remodeling, accelerating CVD development...
September 2, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28865727/altered-mitochondrial-epigenetics-associated-with-subchronic-doxorubicin-cardiotoxicity
#16
André Ferreira, Teresa Cunha-Oliveira, Rui F Simões, Filipa S Carvalho, Ana Burgeiro, Kendra Nordgren, Kendall B Wallace, Paulo J Oliveira
Doxorubicin (DOX), a potent and broad-spectrum antineoplastic agent, causes an irreversible, cumulative and dose-dependent cardiomyopathy that ultimately leads to congestive heart failure. The mechanisms responsible for DOX cardiotoxicity remain poorly understood, but seem to involve mitochondrial dysfunction on several levels. Epigenetics may explain a portion of this effect. Since mitochondrial dysfunction may affect the epigenetic landscape, we hypothesize that this cardiac toxicity may result from epigenetic changes related to disruption of mitochondrial function...
September 1, 2017: Toxicology
https://www.readbyqxmd.com/read/28864889/methylglyoxal-derived-advanced-glycation-end-products-contribute-to-negative-cardiac-remodeling-and-dysfunction-post-myocardial-infarction
#17
Nick J R Blackburn, Branka Vulesevic, Brian McNeill, Cagla Eren Cimenci, Ali Ahmadi, Mayte Gonzalez-Gomez, Aleksandra Ostojic, Zhiyuan Zhong, Michael Brownlee, Paul J Beisswenger, Ross W Milne, Erik J Suuronen
Advanced glycation end-products (AGEs) have been associated with poorer outcomes after myocardial infarction (MI), and linked with heart failure. Methylglyoxal (MG) is considered the most important AGE precursor, but its role in MI is unknown. In this study, we investigated the involvement of MG-derived AGEs (MG-AGEs) in MI using transgenic mice that over-express the MG-metabolizing enzyme glyoxalase-1 (GLO1). MI was induced in GLO1 mice and wild-type (WT) littermates. At 6 h post-MI, mass spectrometry revealed that MG-H1 (a principal MG-AGE) was increased in the hearts of WT mice, and immunohistochemistry demonstrated that this persisted for 4 weeks...
September 1, 2017: Basic Research in Cardiology
https://www.readbyqxmd.com/read/28858301/activation-of-aldehyde-dehydrogenase-2-slows-down-the-progression-of-atherosclerosis-via-attenuation-of-er-stress-and-apoptosis-in-smooth-muscle-cells
#18
Mei-Yan Yang, Ya-Bin Wang, Bo Han, Bo Yang, Yu-Wei Qiang, Yan Zhang, Zhao Wang, Xu Huang, Jie Liu, Yun-Dai Chen, Jun Ren, Feng Cao, Yong Xu
Aldehyde dehydrogenase 2 (ALDH2) is a key mitochondrial enzyme in the metabolism of aldehydes and may have beneficial cardiovascular effects for conditions such as cardiac hypertrophy, heart failure, myocardial I/R injury, reperfusion, arrhythmia, coronary heart disease and atherosclerosis. In this study we investigated the role of ALDH2 in the progression of atherosclerosis and the underlying mechanisms, with a focus on endoplasmic reticulum (ER) stress. A clinical study was performed in 248 patients with coronary heart disease...
August 31, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28855643/a-new-chimeric-natriuretic-peptide-cnaac-for-the-treatment-of-left-ventricular-dysfunction-after-myocardial-infarction
#19
Shu-Miao Zhang, Hong-Lin Zhao, Xiao-Ming Gu, Juan Li, Na Feng, Yue-Min Wang, Rong Fan, Wen-Sheng Chen, Jian-Ming Pei
An innovative natriuretic peptide analog named CNAAC (structurally consisting of the C-terminus and ring of ANP and the N-terminus of CNP) that has been shown to exhibit potent vasodilatory, diuretic, and hypotensive effects in our previous study was evaluated for the treatment of left ventricular dysfunction following myocardial infarction. The temporal relaxation effect and metabolic status of CNAAC were determined. A myocardial ischemic model was established. Rats were randomly divided into Sham, MI, MI-ANP, MI-CNP, MI-VNP, and MI-CNAAC groups...
August 30, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28846098/the-metabolic-effects-of-gdf15-are-mediated-by-the-orphan-receptor-gfral
#20
Paul J Emmerson, Feng Wang, Yong Du, Qian Liu, Richard T Pickard, Malgorzata D Gonciarz, Tamer Coskun, Matthew J Hamang, Dana K Sindelar, Kimberly K Ballman, Lisa A Foltz, Avinash Muppidi, Jorge Alsina-Fernandez, Gavin C Barnard, Jason X Tang, Xilin Liu, Xudong Mao, Robert Siegel, John H Sloan, Pamela J Mitchell, Bei B Zhang, Ruth E Gimeno, Bei Shan, Xinle Wu
Growth/differentiation factor 15 (GDF15), also known as MIC-1, is a distant member of the transforming growth factor-β (TGF-β) superfamily and has been implicated in various biological functions, including cancer cachexia, renal and heart failure, atherosclerosis and metabolism. A connection between GDF15 and body-weight regulation was initially suggested on the basis of an observation that increasing GDF15 levels in serum correlated with weight loss in individuals with advanced prostate cancer. In animal models, overexpression of GDF15 leads to a lean phenotype, hypophagia and other improvements in metabolic parameters, suggesting that recombinant GDF15 protein could potentially be used in the treatment of obesity and type 2 diabetes...
August 28, 2017: Nature Medicine
keyword
keyword
110150
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"